New mRNA shingles shot shows promise in early trial
NCT ID NCT06375512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new mRNA vaccine called IN001 for preventing shingles in 150 healthy adults aged 50 to 69. The main goals were to check the vaccine's safety, side effects, and how well it triggers the immune system. Researchers gave different doses to find the best balance of protection and tolerability.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HERPES ZOSTER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CenExel
Hollywood, Florida, 33024, United States
-
Emeritus Research Pty Ltd
Sydney, New South Wales, 2019, Australia
-
Emeritus Research Pty Ltd
Melbourne, Victoria, 3124, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mRNA technology outsmart shingles? a new vaccine trial aims to find out
- Shingles in cancer patients: a hidden cost burden?
- Shingles vaccine protection tested over 6 years in 24,740 adults
- New gel promises shingles pain relief in minutes
- Shingles shot may shield brain: 33,000 seniors test dementia link
- New shingles vaccine trial aims to protect millions over 40